O
Olaf Loosveld
Researcher at Rotterdam University of Applied Sciences
Publications - 26
Citations - 952
Olaf Loosveld is an academic researcher from Rotterdam University of Applied Sciences. The author has contributed to research in topics: Colorectal cancer & Bevacizumab. The author has an hindex of 11, co-authored 21 publications receiving 823 citations.
Papers
More filters
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.
Sabine Venderbosch,Johannes H. W. de Wilt,Steven Teerenstra,Olaf Loosveld,Aart van Bochove,Harm Sinnige,Geert-Jan Creemers,Margot E T Tesselaar,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +10 more
TL;DR: It is indicated that resection of the primary tumor is a prognostic factor for survival in stage IV CRC patients and the potential bias of these results warrants prospective studies on the value of resections of primary tumor in this setting.
Journal ArticleDOI
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Paul Hamberg,Monique M.E.M. Bos,Hans J Braun,Jacqueline M. Stouthard,Gert A. van Deijk,Frans L. G. Erdkamp,Iris N. van der Stelt-Frissen,M. Bontenbal,Geert-Jan Creemers,Johanneke E.A. Portielje,J.F.M. Pruijt,Olaf Loosveld,Willem M. Smit,Erik W. Muller,Paul I.M. Schmitz,Caroline Seynaeve,Jan G. M. Klijn +16 more
TL;DR: First-line treatment in patients with MBC with H→D resulted in a similar PFS compared with H+D, but the response rate was lower and the overall survival nonsignificantly shorter.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).
Miriam Koopman,Lieke H.J. Simkens,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E. de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jacobus J. M. van der Hoeven,Peter Nieboer,Jürgen Braun,Rob L. H. Jansen,Janny G. Haasjes,Annemieke Cats,J. Wals,Linda Mol,Otilia Dalesio,Harm van Tinteren,Cornelis J. A. Punt +19 more
TL;DR: The CAIRO3 study investigated the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation in mCRC pts not progressing during induction treatment withCAPOX-B.
Journal ArticleDOI
Self-Expanding Metal Stents for Palliative Treatment of Superior Vena Caval Syndrome
TL;DR: The results suggest that when used for this purpose, the new Wallstent is more thrombogenic at 2 weeks than the Z-stent.